PROJECT SUMMARY/ABSTRACT The Rodent Genetic Engineering Laboratory Shared Resource (RGEL) supports all Perlmutter Cancer Center (PCC) members and their colleagues with expert, affordable, and cost- and time-effective services for the creation of genetically modified mouse models (GEMMs). RGEL is essential to the four PCC Programs’ desire to create ever more complex, accurate genetic models of human cancer; during the funding period, 25 funded grants and 64 publications used RGEL data. RGEL is directed by Sang Yong Kim, PhD, Associate Professor of Pathology, who has more than 30 years of experience in rodent and small animal genetic engineering. He and his team of three highly trained scientists provide state-of-the-art and cutting-edge services for the de novo creation and derivation of transgenic, knockout (KO), and knock-in (KI) mice, re-derivation of mutant mice, gene targeting in mESC, and an extensive array of genotyping capabilities. RGEL is located in the Science Building, occupying 1130 sq. ft of dedicated space with a barrier specific pathogen-free (SPF) environment laboratory, animal housing, and a non-barrier laboratory. Its unique capabilities and high level of expertise make RGEL an essential resource for multiple PCC members. To ensure ongoing alignment with PCC investigator needs, RGEL obtains yearly surveys and meets regularly with and internal advisory board comprising PCC members and other NYU faculty to discuss potential future opportunities and utilization of resources. RGEL is continually innovating, evaluating, and developing emerging technologies to extend the breadth of our scientific and technical expertise. The rapid incorporation of new technologies and internal development of innovative procedures by RGEL staff ensure that the four PCC Research Programs have access to cutting-edge expertise for rapidly introducing critical mutations into the mouse germline without the need to rely on outside vendors, which are more expensive and have lengthy timelines. The Specific Aims of RGEL are: 1) To provide PCC members with access to, and expertise in, cost-effective, cutting-edge genetic engineering services for mouse model generation, ensuring state-of-the-art support for pre-clinical research, 2) To provide PCC members with mouse models for preclinical validation of target genes for therapeutic and drug screening in a timely fashion, and 3) To advance innovative and novel approaches for genome engineering in mESC for PCC members.